Showing results (411-420 of 604) with videos related to

Sort By:
Pageof 61
Molecular Pharmaceutics|November 27, 2012
Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomesGunter Almer, Daniela Frascione, Isabella Pali-Schöll, et al.
Nature Communications|March 17, 2022
Nonlinear down-conversion in a single quantum dotB Jonas, D Heinze, E Schöll, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 28, 2004
Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse modelI Schöll, A Weissenböck, E Förster-Waldl, et al.
Biological Psychiatry|November 19, 2019
Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo StudiesThomas Vogels, Antoine Leuzy, Claudia Cicognola, et al.
BMC Pulmonary Medicine|December 18, 2021
Quality of life and asthma control in pregnant women with asthmaNasrin Fazel, Michael Kundi, Erika Jensen-Jarolim, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 22, 2005
Occupational sensitization to ribosome-inactivating proteins in researchersK Szalai, I Schöll, E Förster-Waldl, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 12, 2021
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advancesJoyce R Chong, Nicholas J Ashton, Thomas K Karikari, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersStamatia Karagianni, Alexis Moscoso Rial, Martijn van Essen, et al.
International Journal of Geriatric Psychiatry|June 29, 2018
Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairmentMitzi M Gonzales, Philip S Insel, Craig Nelson, et al.
Pageof 61